|
1
|
Zeisel MB, Lucifora J, Mason WS, Sureau C,
Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, et
al: Towards an HBV cure: State-of-the-art and unresolved questions
- report of the ANRS workshop on HBV cure. Gut. 64:1314–1326. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Papastergiou V, Lombardi R, Macdonald D
and Tsochatzis EA: Global epidemiology of hepatitis B virus (HBV)
infection. Curr Hepat Rep. 14:171–178. 2015. View Article : Google Scholar
|
|
3
|
Roberts H, Kruszon-Moran D, Ly KN, Hughes
E, Iqbal K, Jiles RB and Holmberg SD: Prevalence of chronic
hepatitis B virus (HBV) infection in U.S. households: National
Health and Nutrition Examination Survey (NHANES), 1988–2012.
Hepatology. 63:388–397. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luo G, Feng X, Huang Y, Yi T, Wang D, Guo
X, Yan H and Zhang G: Effects of antiviral therapy on the cellular
immune response in patients with chronic hepatitis B. Mol Med Rep.
11:1284–1291. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lamb C and Arbuthnot P: Activating the
innate immune response to counter chronic hepatitis B virus
infection. Expert Opin Biol Ther. 16:1517–1527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Filippelli M, Garozzo MT, Capizzi A, Spina
M, Manti S, Tardino L, Salpietro C and Leonardi S: Immune response
to hepatitis B virus vaccine in celiac subjects at diagnosis. World
J Hepatol. 8:1105–1109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Himaja N and Shama SN: Herbal wealth for
hepatotoxicity: A review. Asian J Pharm Clin Res. 8:3–9. 2015.
|
|
8
|
Gonzalez SA and Keeffe EB: Chronic
hepatitis B and C: Update on therapy. Future Virol. 4:437–452.
2015. View Article : Google Scholar
|
|
9
|
World Health Organization (WHO), . WHO
Guidelines Approved by the Guidelines Review Committee: WHO
Guidelines for the Prevention, Care and Treatment of Persons with
Chronic Hepatitis B Infection. World Health Organization; Geneva:
2015
|
|
10
|
The Korean Association for the Study of
the Liver (KASL): KASL Clinical Practice Guidelines: Management of
chronic hepatitis B. Clin Mol Hepatol. 18:109–162. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lv J, Lin S, Peng P, Cai C, Deng J, Wang
M, Li X, Lin R, Lin Y, Fang A, et al: Arenobufagin activates p53 to
trigger esophageal squamous cell carcinoma cell apoptosis in vitro
and in vivo. Onco Targets Ther. 10:1261–1267. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hong CA and Nam YS: Functional
nanostructures for effective delivery of small interfering RNA
therapeutics. Theranostics. 4:1211–1232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao BB, Zheng SJ, Gong LL, Wang Y, Chen
CF, Jin WJ, Zhang D, Yuan XH, Guo J, Duan ZP, et al: T lymphocytes
from chronic HCV-infected patients are primed for
activation-induced apoptosis and express unique pro-apoptotic gene
signature. PLoS One. 8:e770082013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Somal A, Aggarwal A and Upadhyay RC:
Effect of thermal stress on expression profile of apoptosis related
genes in peripheral blood mononuclear cells of transition Sahiwal
cow. Iran J Vet Res. 16:137–143. 2015.PubMed/NCBI
|
|
15
|
McIlwain DR, Berger T and Mak TW: Caspase
functions in cell death and disease. Cold Spring Harb Perspect
Biol. 7:a0086562015. View Article : Google Scholar
|
|
16
|
Karev VE: Fas, FasL, and bcl-2 expression
on hepatic intralobar lymphocytes in different variants of the
natural course of chronic HBV and HCV infection and in its
outcomes. Arkh Patol. 76:16–21. 2014.(In Russian). PubMed/NCBI
|
|
17
|
Martins D'Oliveira F, Gomes BC, Rodrigues
AS and Rueff J: Genetic susceptibility in acute pancreatitis:
Genotyping of GSTM1, GSTT1, GSTP1, CASP7, CASP8, CASP9, CASP10,
LTA, TNFRSF1B, and TP53 gene variants. Pancreas. 46:71–76. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meng P, Yoshida H, Tanji K, Matsumiya T,
Xing F, Hayakari R, Wang L, Tsuruga K, Tanaka H, Mimura J, et al:
Carnosic acid attenuates apoptosis induced by amyloid-β 1–42 or
1–43 in SH-SY5Y human neuroblastoma cells. Neurosci Res. 94:1–9.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo X, Dong Z, Yamada S, Li Y, Guo Y, Shen
S, Liang J, Tanimoto A and Guo W: Association of Casp3 microRNA
target site (1049216) SNP with the risk and progress of cervical
squamous cell carcinoma. Int J Gynecol Cancer. 27:206–213. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peng CY, Hsieh TC, Hsieh TY, Tseng KC, Lin
CL, Su TH, Tseng TC, Lin HH, Wang CC and Kao JH: HBV-DNA level at 6
months of entecavir treatment predicts HBeAg loss in HBeAg-positive
chronic hepatitis B patients. J Formos Med Assoc. 114:308–313.
2015. View Article : Google Scholar : PubMed/NCBI
|
